Biliary cirrhosis associated with WDR19-related ciliopathy in siblings.

J Hepatol

Division of Gastroenterology and Hepatology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, USA.

Published: December 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2024.07.033DOI Listing

Publication Analysis

Top Keywords

biliary cirrhosis
4
cirrhosis associated
4
associated wdr19-related
4
wdr19-related ciliopathy
4
ciliopathy siblings
4
biliary
1
associated
1
wdr19-related
1
ciliopathy
1
siblings
1

Similar Publications

Background And Aim: Although Kasai surgery has saved many patients with biliary atresia, the long-term survival rate remains low. Recently, cell therapy has been explored as a potential strategy to improve post-surgical survival. This study aims to evaluate the safety and outcomes of allogeneic umbilical cord mesenchymal stem cell (UC-MSC) infusion in management of liver cirrhosis due to Biliary Atresia after Kasai Operation.

View Article and Find Full Text PDF

[Primary biliary cholangitis-Update on diagnostics, risk stratification and new treatment options].

Inn Med (Heidelb)

September 2025

Bereich Hepatologie, Medizinische Klinik II, Universitätsklinikum Leipzig, Leipzig, Deutschland.

Primary biliary cholangitis (PBC) is a chronic inflammatory, autoimmune-mediated liver disease that progresses to fibrosis and cirrhosis if left untreated. In addition to preventing complications, the management of burdensome symptoms, particularly pruritus, represents a key therapeutic goal. Ursodeoxycholic acid (UDCA) is the established first-line treatment; however, up to 40% of patients show an inadequate response and require second-line treatment.

View Article and Find Full Text PDF

Introduction: Failure to rescue (FTR) is mortality after a major complication. FTR may be an effective quality metric in liver transplantation (LT). However, there is a paucity of nationwide data on the rates and effects of FTR on outcomes.

View Article and Find Full Text PDF

Background: Ursodeoxycholic acid (UDCA) is the first-line therapeutic agent for primary biliary cholangitis (PBC). However, a subset of patients exhibit a suboptimal response to UDCA, and reliable predictive biomarkers remain elusive. Studies have implicated plasma microRNAs (miRNAs) in the pathophysiological progression of PBC, with certain miRNAs demonstrating potential as diagnostic and disease progression biomarkers.

View Article and Find Full Text PDF